JNJ stock: buy or sell?
November 19th, 2019
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide.
Should I buy JNJ stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Following a trading plan helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Just 1 of our buy setups matches with Johnson & Johnson stock now:
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||Yes|
|100d MA crossing up 200d MA||No|
Is Johnson & Johnson stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we collected 14 ratings published for JNJ stock in the last 30 days. The general sentiment of these ratings is bullish for JNJ stock, with 11 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-8-27||Morgan Stanley||n/a||Equal Weight|
|2019-8-27||Goldman Sachs Group||n/a||Buy|
|2019-8-27||Credit Suisse Group||n/a||Buy|
|2019-7-18||Credit Suisse Group||n/a||Buy|
|2019-7-16||Royal Bank of Canada||n/a||Buy|
|2019-7-16||Bank of America||n/a||Hold|
|2019-7-12||Credit Suisse Group||n/a||Outperform|
|2019-5-6||Wells Fargo & Co||n/a||Outperform|
|2019-5-28||Goldman Sachs Group||n/a||Buy|
|2019-5-16||Credit Suisse Group||n/a||Outperform|
|2019-4-17||Morgan Stanley||Equal Weight||Equal Weight|
|2019-4-17||Credit Suisse Group||Outperform||Outperform|
JNJ stock analysis
Johnson & Johnson stayed constant a neutral -0.01% and closed at $134.82.
Johnson & Johnson shares stayed stable -0.01% to $134.82 yesterday. In the last 5 days when JNJ stock price broke up the SMA200d line, it gained $3.86 (2.95%).
After climbing for 4 weeks, this week Johnson & Johnson remained steady a tight -0.09%, closing at $134.82.
Since last week when JNJ stock price broke up the SMA40w line, it gained $1.82 (1.37%). Far behind is the all-time high Johnson & Johnson recorded early December but price is just -7.60% below that top.
JNJ stock price history
JNJ stock went public on August 18th, 1980 with a price of $0.011. Since then, JNJ stock surged a 1,348,100.00%, with an average of 34,566.70% per year. If you had invested right after JNJ's IPO a $1,000 in JNJ stock in 1980, it would worth $13,481,000.00 today.
1: Adjusted price after possible price splits or reverse-splits.
JNJ stock historical price chart
JNJ stock reached all-time highs on December with a price of $145.91.
JNJ stock price target is $152.90Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. You should not follow the analysts' JNJ stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we found 12 price targets for Johnson & Johnson stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-8-27||Goldman Sachs Group||Set Price Target||n/a||$169.00||-|
|2019-8-27||Credit Suisse Group||Set Price Target||n/a||$156.00||-|
|2019-7-18||Credit Suisse Group||Set Price Target||n/a||$156.00||-|
|2019-7-17||Raymond James||Lowers Target||$147.00||$146.00||-0.7%|
|2019-7-16||Bank of America||Reiterates||n/a||$150.00||-|
|2019-7-12||Credit Suisse Group||Initiates||n/a||$156.00||-|
|2019-5-6||Wells Fargo & Co||Reiterates||$152.00||$157.00||3.3%|
|2019-5-16||Credit Suisse Group||Raises Target||$152.00||$156.00||2.6%|
|2019-4-17||Raymond James||Raises Target||$145.00||$147.00||1.4%|
|2019-4-17||Morgan Stanley||Raises Target||$134.00||$145.00||8.2%|
|2019-4-17||Credit Suisse Group||Raises Target||$151.00||$152.00||0.7%|
Financials and fundamental analysis
Earnings date and Earnings per ShareSince April, when Johnson & Johnson posted its last earnings report, it . Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Johnson & Johnson annual turnover jumped a great 6.71% to $81,581.00 million dollars from $76,450.00 marked in 2017. However, its income margin (compared to sales) boosted to 18.75%, that is $15,297.00 million. Johnson & Johnson fiscal year ends in December, and to compare its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Johnson & Johnson TTM sales up to March 2019 were $81,593.00 and income $14,679.00 M dollars. If we compare this TTM figures with the last reported annuality, we can esteem Johnson & Johnson business evolution since December 2018: Annual revenues up to March, compared to lastest yearly report, stayed constant a neutral 0.01%. In line, profit margin (net income/revenues) remained stable at 18.75%.
|2013||$71,260 M||-||$13,830 M19.4%||-|
|2014||$74,331 M||4.31%||$16,323 M22.0%||18.03%|
|2015||$70,074 M||-5.73%||$15,409 M22.0%||-5.60%|
|2016||$71,890 M||2.59%||$16,540 M23.0%||7.34%|
|2017||$76,450 M||6.34%||$1,300 M1.7%||-92.14%|
|2018||$81,581 M||6.71%||$15,297 M18.8%||1,076.69%|
|TTM||$81,593 M||0.01%||$14,679 M18.0%||-4.04%|
Quarterly financial resultsJohnson & Johnson posted $20,021.00 M in sales for 2019-Q1, a -1.83% less compared to previous quarter. Reported quarter earnings marked $3,749.00 million with a profit margin of 18.73%. Profit margin appreciated a 3.81% compared to previous quarter when profit margin was 14.92%. When comparing sales to same quarter last year, Johnson & Johnson sales marked a tight move and remained steady a 0.06%.
|2017-Q2||$18,850 M||-||$3,830 M20.3%||-|
|2017-Q3||$19,650 M||4.24%||$3,760 M19.1%||-1.83%|
|2017-Q4||$20,195 M||2.77%||$-10,713 M-53.0%||-384.92%|
|2018-Q1||$20,009 M||-0.92%||$4,367 M21.8%||-140.76%|
|2018-Q2||$20,830 M||4.10%||$3,954 M19.0%||-9.46%|
|2018-Q3||$20,348 M||-2.31%||$3,934 M19.3%||-0.51%|
|2018-Q4||$20,394 M||0.23%||$3,042 M14.9%||-22.67%|
|2019-Q1||$20,021 M||-1.83%||$3,749 M18.7%||23.24%|
Johnson & Johnson ownershipWhen you are planning to buy a company, it's always worth to review its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Johnson & Johnson, 0.07% of all outstanding shares are owned by its staff.
In case of Johnson & Johnson stock, 69.23% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for JNJ stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Johnson & Johnson:
|Market cap||$354.6 B||$149.2 B||$110.8 B||$110.5 B||$149.1 B|
|Total shares||2,630.0 M||1,770.0 M||2,490.0 M||960.1 M||1,340.0 M|
|Float shares||2,630.0 M||1,760.0 M||2,450.0 M||842.1 M||1,340.0 M|
|- Institutional holdings (%)||69.2%||76.5%||11.0%||81.5%||84.2%|
|- Insider holdings (%)||0.1%||0.7%||0.0%||0.1%||0.1%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Tuesday, November 19th, 2019|
|Day range||$134.39 - $135.19|
|Average true range||$1.82|
|50d mov avg||$131.05|
|100d mov avg||$131.21|
|200d mov avg||$133.60|
Johnson & Johnson performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. For Johnson & Johnson, the benchmark is made against , GlaxoSmithKline, Eli Lilly and, Medtronic, Merck, Novartis, Pfizer, and Stryker.
|LLYEli Lilly and||5.71%||-0.32%||4.28%|
Johnson & Johnson competitorsOne check before trading any stock is to have a look a list of its competitors, in this case for Johnson & Johnson. We picked 9 companies as Johnson & Johnson competitors as they are in the same industry or have similar market objectives.
- GlaxoSmithKline (GSK)
- Eli Lilly and (LLY)
- Medtronic (MDT)
- Merck (MRK)
- Novartis (NVS)
- Pfizer (PFE)
- Stryker (SYK)
Latest JNJ stock news
- InvestorPlaceWhy Johnson & Johnson Stock Isn’t a Buy… YetJuly 29, 2019
- Seeking AlphaJohnson & Johnson's Stock May Be Too Cheap In A Low Interest Rate WorldJuly 24, 2019
- InvestorPlaceIs Johnson & Johnson Stock Losing Its Shine?July 24, 2019
- InvestorPlaceJohnson & Johnson Could Turn Around After its Strong EarningsJuly 24, 2019
- InvestorPlaceJohnson & Johnson Earnings: JNJ Stock Dips Despite Q2 Beat, Raised GuidanceJuly 16, 2019